Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial)

Conflicts of interest: J. B.'s institution received grants, consulting fee/honorarium, travel support for meetings, fees for data monitoring, and provision of medicine/administrative support from Novartis Pharmaceuticals Corporation for this study. His institution received financial compensation for consulting, grants, honoraria, development of educational programs, and travel reimbursement from Novartis Pharmaceuticals Corporation for non-study-related projects. E. A.-A., S. E., S. L., and G. W. are employees of Novartis Pharmaceuticals Corporation. S. E., E. A.-A., and G. W. own stock in Novartis Pharmaceuticals Corporation. R. B. received compensation for overhead support per patient enrolled in the study. T. L. received compensation for reporting/monitoring patients in the study. R. C. has no potential conflicts of interest to disclose.

Correspondence to: James R. Berenson, MD, Institute for Myeloma & Bone Cancer Research, 9201 West Sunset Boulevard, Suite 300, West Hollywood, CA 90069; telephone: (310) 623–1214; fax: (310) 623–1120